v3.26.3
Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Cash flows from operating activities          
Net Loss $ (4,623) $ (1,174) $ (8,344) $ (5,213)  
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation of property and equipment     74 73  
Amortization of intangible asset     103 66  
Amortization of customer incentive asset     22  
Provision for credit losses     46  
Stock-based compensation     1,309 176  
Amortization of right-of-use assets     215 65  
Amortization of convertible note discount     294  
Changes in fair value of convertible notes at fair value and warrant liability     (91) 1,405  
Change in fair value of forward purchase derivative liability 2,212 604  
Accretion of cumulative mandatorily redeemable common and preferred stock liability     83 71  
Loss on extinguishment of debt     391  
Gain on extinguishment of payable (105) (612)  
Unrealized foreign exchange gain/(loss)     (7)  
Changes in operating assets and liabilities:          
Accounts receivable, current, net     (208) 87  
Unbilled revenue     (20) 56  
Prepaid expenses and other current assets     185 (44)  
Accounts receivable, net     4  
Other assets     4 (7)  
Accounts payable     (156) 1,989  
Operating lease liabilities     (232) (53)  
Accrued expenses and other current liabilities     1,963 461  
Deferred revenue     (54)  
Net cash used in operating activities     (4,807) (488)  
Cash flows from investing activities          
Costs capitalized for internally developed software     (157) (72)  
Purchases of property and equipment     (27) (8)  
Net cash used in investing activities     (184) (80)  
Cash flows from financing activities          
Proceeds from Convertible notes payable, current     2,050 180  
 Repayment of Convertible notes payable, current     (224)  
Proceeds received from sales of forward purchase agreement shares     679  
 Payment of director and officer insurance liability (short term debt)     (376)  
Proceeds from director and officer insurance liability (short term debt)     98  
Payment of deferred transaction costs     (5)  
Net cash (used in) / provided by financing activities     2,227 175  
Effect of exchange rate changes on cash and cash equivalents     (4) (1)  
Net change in cash and cash equivalents     (2,767) (394)  
Cash and cash equivalents at beginning of the period     4,221 500 $ 500
Cash and cash equivalents at end of the period $ 1,454 $ 106 1,454 106 $ 4,221
Supplemental disclosures of cash flow information          
Cash paid for income taxes     22 18  
Cash paid for interest     12  
Non-cash investing and financing activities:          
Deemed dividend related to shortfall warrant modification     84  
Common Stock issued upon cashless exercise of stock options     39 707  
Unpaid deferred transaction costs as of the end of the period     507  
Waiver of deferred transaction costs as of the end of the period     505  
Issuance of shares vested upon repayment and forgiveness of 2023 Promissory Notes     3  
Warrants issues in connection with new Convertible Notes (Refer note 6)     231  
Shortfall warrant amendment (Refer note 16)     494  
Issuance of common stock as consideration payable to customer (Refer note 4)     578    
Issuance of common stock to settle outstanding severance pay of employees (Refer note 9)     460  
Issuance of common stock to settle outstanding invoices of vendor (Refer note 18)     1,298  
Adjustment of share subscription receivable on account of partial early termination of forward contract (Refer note 15)     9,588    
(Loss)/Gain on extinguishment of debt     $ (391)